San Antonio Breast Cancer Symposium (SABCS)

High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.

Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.

Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.

Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.

Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.

Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.

Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.

Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.

It may be possible to use anastrozole plus palbociclib, trastuzumab, and pertuzumab in place of chemotherapy in the frontline setting for hormone receptor–positive, HER2-positive metastatic breast cancer, says Amy Tiersten, MD.

A future phase 2 trial may compare anastrozole plus a CDK4/6 inhibitor and trastuzumab or pertuzumab with chemotherapy plus trastuzumab and pertuzumab in hormone receptor–positive, HER2-positive metastatic breast cancer.

Adding trastuzumab emtansine to tucatinib appears to significantly improve progression-free survival in patients with metastatic HER2-positive breast cancer, says Sara Hurvitz, MD, FACP.

It is important to look at different assays beyond immunohistochemistry to better gather information and potentially predict the activity of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer, says Paolo Tarantino, MD.

Combining ribociclib with nonsteroidal aromatase inhibitor treatment also produces relapse-free survival and distant disease-free survival benefits in patients with HR-positive, HER2-negative early-stage breast cancer.

More funding is necessary for additional trials investigating the potential clinical benefit of an alpha-lactalbumin vaccine for patients with high-risk operable triple-negative breast cancer and those at high risk of developing the disease, says G. Thomas Budd, MD.

Treatment with atezolizumab among patients with HER2-positive breast cancer in the phase 3 APTneo Michelangelo trial produces no major tolerability issues, says Luca Gianni, MD.

Findings from a phase 2a study support further development of a regimen including zanidatamab, palbociclib, and fulvestrant in those with HER2-positive, hormone receptor–positive breast cancer.

Latin American patients appear more likely to be diagnosed with aggressive early-stage breast cancer based on factors including metabolics and genetics, according to findings from the FLEX study.

All dose-limiting toxicities with SIM0270 in a phase 1 trial appear to be manageable with dose reductions in those with estrogen receptor–positive, HER2-negative breast cancer.

Investigators observe no new safety signals with trastuzumab emtansine as a treatment for HER2-positive breast cancer after 8 years of follow-up in the phase 3 KATHERINE study.

Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.

Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

Quality of life also appears to be maintained with elacestrant in estrogen receptor–positive or HER2-negative ESR1-mutated breast cancer in the phase 3 EMERALD trial.

Safety findings in the phase 1b DESTINY-Breast08 are comparable with prior reports of trastuzumab deruxtecan and endocrine therapy in HER2-low hormone receptor–positive metastatic breast cancer.

Data from the phase 3 TROPION-Breast01 trial support datopotamab deruxtecan as a potential treatment option for patients with endocrine-resistant, hormone receptor–positive, metastatic breast cancer, says Aditya Bardia, MD, MPH.

Trastuzumab deruxtecan produces the longest time to next treatment in patients with HER2-positive or stable HER2-low advanced breast cancer in the RELIEVE study.